SAN FRANCISCO, May 03, 2018 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, today announces financial results for the three months ended March 31, 2018.
Q1 2018 Highlights
“In the first quarter we made progress towards our near and long term goals. During the quarter, we completed an equity offering, adding $21.7 million of cash and strengthening our balance sheet. In addition, this month we have taken steps to reduce our operating expenses by implementing a restructuring designed to streamline the company and increase productivity in our commercial operations and our product development process.” said Interim Chief Executive Officer Scott Flora. “PhotonBlade continues to be an outstanding product. We saw a 23% increase in accounts ordering PhotonBlade during the quarter demonstrating continued adoption in the market. While there is still work to be done to create a balanced approach to selling our entire disposable product portfolio, I am excited by the opportunity we have in front of us and confident we can demonstrably expand the Invuity franchise.”
Revenue was $9.5 million in the first quarter of 2018, up 5.3% from revenue of $9.0 million in the first quarter of 2017 driven primarily by strong market acceptance of PhotonBlade.
Disposable revenue was $8.6 million in the first quarter of 2018, up 21.7% from revenue of $7.0 million in the first quarter of 2017. Disposable revenue comes from the sale of single use devices; waveguides that are attached to retractors, illuminated aspirators – both Yankauer and Frazier designs – and most recently the addition of PhotonBlade. These revenues are driven by per procedure adoption and represent the primary driver of the Company’s growth.
Gross margin for the first quarter was 69.3% compared to 76.7% for the same period in 2017. The consolidated gross margin was primarily impacted on a comparative basis by the increase in sales of PhotonBlade, which currently has a lower gross margin than other disposable products. Progress continues to be made on cost reduction programs to improve PhotonBlade margins.
Total operating expenses for the first quarter of 2018 were $17.0 million, including $3.0 million in severance and litigation expenses, compared to $17.3 million, including $1.4 million in severance and litigation expenses, in the prior year period.
The net loss for the first quarter of 2018 was $11.2 million, or $0.62 loss per share, compared to a net loss of $13.2 million, or $0.78 loss per share, for the first quarter of 2017.
The Company's balance sheet as of March 31, 2018 included total cash, cash equivalents and short-term investments of $32.6 million.
In May the Company implemented a corporate restructuring to streamline the business and increase productivity in the Company’s commercial operations and product development process. It is anticipated this restructuring will reduce operating expenses by approximately $6 million on an annualized basis.
For 2018 Invuity continues to expect revenue to exceed $46 million and disposable revenue to grow in excess of 25%.
Invuity's management will discuss the Company's financial results for the first quarter ended March 31, 2018 and provide a general business update during a conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time today, May 3, 2018. To join the live call, participants may dial 1-877-556-8638 (U.S.) or 1-615-247-0174 (International), Conference ID: 9299518. To listen to the live call via Invuity's website, go to www.invuity.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call for a period of 90 days in the Events & Presentations section of the website.
Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The Company’s patented Intelligent Photonics® technology delivers enhanced visualization, which facilitates surgical precision, efficiency and safety. Clinical applications include women’s health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic and general surgery. Invuity is headquartered in San Francisco, CA.
This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding financial projections for 2018 and expectations regarding our restructuring efforts, planned reduction in operating expenses, adoption of PhotonBlade, future product introductions, future sales and marketing initiatives, and market opportunities. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company's devices; the Company's ability to demonstrate to and gain approval from hospitals to use the Company's devices; the highly competitive business environment for surgical medical devices; the Company's ability to sell its devices at prices that support its current business strategies; the adequacy of the Company’s existing cash resources and funding requirements; difficulty forecasting future financial performance; protection of the Company's intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which are on file with the Securities and Exchange Commission.
Chief Financial Officer
|Condensed Consolidated Statements of Operations|
|(In thousands, except share and per share amounts)|
|Three Months Ended March 31,|
|Cost of goods sold||2,923||2,099|
|Research and development||1,882||2,428|
|Selling, general and administrative||15,112||14,853|
|Total operating expenses||16,994||17,281|
|Loss from operations||(10,412||)||(10,357||)|
|Other expense, net||(66||)||(127||)|
|Loss on extinguishment of debt||—||(2,303||)|
|Net loss and comprehensive loss||$||(11,197||)||$||(13,217||)|
|Net loss per common share, basic and diluted||$||(0.62||)||$||(0.78||)|
|Weighted-average shares used to compute net loss per common share, basic and diluted||18,124,529||16,958,332|
|Condensed Balance Sheets|
|as of March 31, 2018 and December 31, 2017|
|(In thousands, except share and per share amounts)|
|March 31,||December 31,|
|Cash and cash equivalents||$||29,539||$||17,962|
|Restricted cash - current||181||181|
|Accounts receivable, net||6,257||7,421|
|Prepaid expenses and other current assets||1,103||1,274|
|Total current assets||48,853||37,314|
|Property and equipment, net||6,989||7,169|
|Other long-term assets||243||285|
|Liabilities and Stockholders’ Equity (Deficit)|
|Accrued and other current liabilities||6,832||5,179|
|Deferred revenue - short term||44||—|
|Total current liabilities||14,468||14,636|
|Deferred revenue - long term||80||36|
|Commitments and contingencies (Note 8)|
|Stockholders’ equity (deficit):|
|Preferred stock, $0.001 par value—10,000,000 shares authorized at March 31, 2018 and December 31, 2017; no shares issued and outstanding at March 31, 2018 and December 31, 2017||—||—|
|Common stock, $0.001 par value—100,000,000 shares authorized at March 31, 2018 and December 31, 2017; 24,023,517 and 17,179,258 shares issued and outstanding at March 31, 2018 and December 31, 2017||24||17|
|Additional paid-in capital||207,869||185,255|
|Total stockholders’ equity (deficit)||10,562||(862||)|
|Total liabilities and stockholders’ equity (deficit)||$||56,812||$||45,495|